Click on a filter below to refine your search. Remove a filter to broaden your search.
CYP2D6-inhibiting antidepressants were linked to worse outcomes than CYP2D6-neutral antidepressants when used with CYP2D6-metabolizing opioids.
Excellent tolerability was seen, with no changes in blood pressure, minimal reports of sedation and minimal dissociation.
Potential class-dependent associations may exist, however.
No significant increase was seen with the use of GLP-1 RAs versus SGLT2is or DPP4is among older Medicare beneficiaries.
Metformin displayed a lowest risk for dementia across diverse antidiabetics, while α-glucosidase inhibitors had the highest risk.
Polypharmacy increased, peaking at 43.0% in 2017 to March 2020; hyperpolypharmacy increased during 1999-2000 to 2007-2008.